GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asymchem Laboratories Tianjin Co Ltd (SZSE:002821) » Definitions » Research & Development

Asymchem Laboratories Tianjin Co (SZSE:002821) Research & Development : ¥715 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Asymchem Laboratories Tianjin Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Asymchem Laboratories Tianjin Co's Research & Development for the three months ended in Mar. 2024 was ¥169 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ¥715 Mil.


Asymchem Laboratories Tianjin Co Research & Development Historical Data

The historical data trend for Asymchem Laboratories Tianjin Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asymchem Laboratories Tianjin Co Research & Development Chart

Asymchem Laboratories Tianjin Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 192.52 258.93 387.48 708.89 707.86

Asymchem Laboratories Tianjin Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 162.10 161.37 189.64 194.75 169.44

Asymchem Laboratories Tianjin Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥715 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asymchem Laboratories Tianjin Co  (SZSE:002821) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Asymchem Laboratories Tianjin Co Research & Development Related Terms

Thank you for viewing the detailed overview of Asymchem Laboratories Tianjin Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Asymchem Laboratories Tianjin Co (SZSE:002821) Business Description

Traded in Other Exchanges
Address
No. 6 Dongting Third Street, Economic and Technological Development Zone, Tianjin, CHN, 300457
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development Manufacture Organization solutions throughout the drug development and manufacturing process. The Group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing which focuses on innovation and commercial application of global pharmaceutical technology.
Executives
Xiao Yi Executives
Xu Xiang Ke Directors, executives
Zhou Yan Executives
Chen Chao Yong Executives
Huang Xiao Lian Executives
Yang Jing Director
Executives

Asymchem Laboratories Tianjin Co (SZSE:002821) Headlines

No Headlines